{"id":43076,"date":"2025-10-11T14:43:45","date_gmt":"2025-10-11T06:43:45","guid":{"rendered":"https:\/\/flcube.com\/?p=43076"},"modified":"2025-10-11T14:43:46","modified_gmt":"2025-10-11T06:43:46","slug":"beone-medicines-terminates-patent-dispute-with-abbvies-pharmacyclics-over-btk-inhibitors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43076","title":{"rendered":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>)<\/strong> announced today that it has terminated its patent litigation against <strong>AbbVie\u2019s Pharmacyclics<\/strong> regarding their <strong>BTK inhibitors (BTKi)<\/strong>. The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-background\">Background<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patent Claim Dispute<\/strong> \u2013 The 803 patent, which underpinned Pharmacyclics\u2019 2023 infringement lawsuit, covered a method of use for a BTKi with a specific chemical structure to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).<\/li>\n\n\n\n<li><strong>Clinical Context<\/strong> \u2013 The lawsuit was filed shortly after <strong>BeOne\u2019s BTKi, Brukinsa<\/strong>, defeated Pharmacyclics\u2019 BTKi, Imbruvica, in a phase\u202f3 head\u2011to\u2011head trial for second\u2011line CLL\/SLL.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-resolution\">Resolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Joint Stipulation<\/strong> \u2013 On <strong>September\u202f30,\u202f2025 (U.S. Time)<\/strong>, BeOne and Pharmacyclics signed a joint stipulation to <strong>voluntarily dismiss<\/strong> the related district court litigation with prejudice.<\/li>\n\n\n\n<li><strong>Outcome<\/strong> \u2013 The case is now fully resolved, eliminating the legal uncertainty that had surrounded the 803 patent claims.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implications\">Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Focus<\/strong> \u2013 BeOne can redirect resources toward expanding Brukinsa\u2019s commercial launch and pipeline development.<\/li>\n\n\n\n<li><strong>Market Dynamics<\/strong> \u2013 The dismissal removes a potential barrier to broader adoption of BTK inhibitors within the competitive CLL\/SLL treatment landscape.<\/li>\n\n\n\n<li><strong>Regulatory Landscape<\/strong> \u2013 The decision underscores the importance of robust post\u2011grant review proceedings in shaping the biotech patent ecosystem.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43080,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,61],"tags":[234,2092,847,3046,73,848,33],"class_list":["post-43076","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-legal-ip","tag-abbvie","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-onc","tag-patents","tag-sha-688235","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43076\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43076\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-11T06:43:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-11T06:43:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors\",\"datePublished\":\"2025-10-11T06:43:45+00:00\",\"dateModified\":\"2025-10-11T06:43:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1102.webp\",\"keywords\":[\"AbbVie\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: ONC\",\"Patents\",\"SHA: 688235\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43076#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43076\",\"name\":\"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1102.webp\",\"datePublished\":\"2025-10-11T06:43:45+00:00\",\"dateModified\":\"2025-10-11T06:43:46+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43076\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43076#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43076","og_locale":"en_US","og_type":"article","og_title":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).","og_url":"https:\/\/flcube.com\/?p=43076","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-11T06:43:45+00:00","article_modified_time":"2025-10-11T06:43:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43076#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43076"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors","datePublished":"2025-10-11T06:43:45+00:00","dateModified":"2025-10-11T06:43:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43076"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43076#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","keywords":["AbbVie","BeOne Medicines","HKG: 6160","NASDAQ: ONC","Patents","SHA: 688235","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43076#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43076","url":"https:\/\/flcube.com\/?p=43076","name":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43076#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43076#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","datePublished":"2025-10-11T06:43:45+00:00","dateModified":"2025-10-11T06:43:46+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated its patent litigation against AbbVie\u2019s Pharmacyclics regarding their BTK inhibitors (BTKi). The settlement follows Pharmacyclics\u2019 decision not to appeal the U.S. Patent and Trademark Office\u2019s Final Written Decision that invalidated all contested claims of U.S. Patent\u202fNo.\u202f11,672,803 (the \u201c803 patent\u201d).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43076#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43076"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43076#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","width":1080,"height":608,"caption":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43076#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne Medicines Terminates Patent Dispute with AbbVie\u2019s Pharmacyclics Over BTK Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43076"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43076\/revisions"}],"predecessor-version":[{"id":43081,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43076\/revisions\/43081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43080"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}